Biodegradable Poly(D,L-lactic-co-glycolic acid)-Based Micro/Nanoparticles for Sustained Release of Protein Drugs - A Review by Ansary, Rezaul H et al.
Ansary et al 
Trop J Pharm Res, July 2014; 13(7):   
 
1179 
Tropical Journal of Pharmaceutical Research July 2014; 13 (7): 1179-1190 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 





Biodegradable Poly(D,L-lactic-co-glycolic acid)-Based 
Micro/Nanoparticles for Sustained Release of Protein 
Drugs - A Review 
 
Rezaul H Ansary, Mohamed B Awang and Mokhlesur M Rahman*  
Kulliyyah of Pharmacy, International Islamic University Malaysia, 25200 Kuantan, Malaysia 
 
*For correspondence: Email: mdrahman@iium.edu.my 
 
Received: 10 July 2013        Revised accepted: 16 April 2014 
 
Abstract 
Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) and PLGA-based polymeric nanoparticles are 
widely used for sustained release of protein and peptide drugs. These formulations are usually prepared 
by water/oil/water (W/O/W) and solid/oil/water (S/O/W) double emulsion solvent evaporation method. 
Other methods of preparation are nanoprecipitation, emulsion solvent diffusion and salting-out. This 
review attempts to address the effects of PLGA molecular weight, lactide to glycolide ratio, crystallinity, 
hydrophilicity as well as nanoparticles preparation variables (e.g., homogenizer speed, surfactants 
nature and concentration) on the size, morphology, drug encapsulation efficiency and release profile of 
PLGA mico/nanoparticles. The current knowledge of protein instability during preparation, storage and 
release from PLGA micro/nanoparticles and protein stabilization approaches has also been discussed in 
this review. 
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Biodegradable polymeric nanoparticles are solid 
or semisolid colloidal particles ranging in size 
from 10 to 1000 nm [1]. They consist of both 
micro-and macromolecular substances and can 
be used as drug carriers. The drug can be 
adsorbed, dissolved, entrapped, or encapsulated 
into the nanoparticles matrix. In conventional 
administration, macromolecular drugs such as 
protein and peptide drugs are administered by 
daily, sometimes multiple injections via a 
parenteral route due to their short half life in vivo. 
To improve patient compliance and convenience, 
controlled release formulations of protein and 
peptide drugs have been developed [2-4].  
Over the past three decades, poly(D, L-lactic-co-
glycolic acid) (PLGA) has been investigated 
extensively for developing micro/nanoparticles 
for controlled release of protein and peptide 
drugs due its biodegradability and 
biocompatibility [5-7]. An ideal micro/nanoparticle 
formulation is one which should have high 
encapsulation efficiency, loading capacity, 
sustained and complete release of the 
encapsulated drug with retained structural 
integrity [8,9]. High protein loading and high 
encapsulation efficiency are very important due 
to the extremely high price of pharmaceutical 
proteins. Several protein and peptide -PLGA 
microspheres are currently available in the 
United States and European markets, although 
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they still present various challenges for 
researchers.  
 
In general, the major drawbacks in the 
development of PLGA based micro/nanoparticle 
formulations in protein and peptide d delivery are 
the high initial burst, incomplete release and 
instability of the encapsulated proteins [10-12]. 
Initial burst release means the rapid release of a 
large amount of encapsulated protein. This 
phenomenon is commonly observed in PLGA 
based micro/nanoparticles delivery system. This 
is due to the rapid diffusion of protein molecules 
adsorbed or located at the surface of the PLGA 
micro/nanoparticles. A great amount of the 
loaded protein is not released after a certain 
period of release study either due to protein 
aggregation or adsorption to the strong 
hydrophobic PLGA surfaces resulting in 
incomplete protein release. As a result of the 
degradation of PLGA during the drug release 
process, lactic and glycolic acids are generated, 
thereby resulting in a significant reduction of the 
pH of the microenvironment and denaturation of 
the encapsulated proteins [13,14]. The release 
kinetics of encapsulated protein and peptide 
drugs from PLGA micro and nanoparticles 
depend on a number of factors such as PLGA 
molecular weight, lactide/glycolide ratio, PLGA 
end groups, particle morphology, drug 
distribution, etc [15,16]. This review addresses 
current knowledge on the preparation of PLGA-
based micro/nanoparticles for parenteral and oral 
delivery of protein and peptide drugs with 
particular emphasis on the retention of biological 
activity of encapsulated drugs.  
 




Method of preparation and properties 
 
Among the different classes of biodegradable 
polymers, poly(D,L-lactide-co-glycolide) (PLGA) 
and its homopolymers poly(lactide) (PLA) and 
poly(glycolide) (PGA) are the most widely used 
biodegradable polymers. These polymers have 
been approved by the United States Food and 
Drug Administration (FDA) for drug delivery due 
to their excellent biocompatibility, 
biodegradability and mechanical strength [5]. 
They can degrade by non-enzymatic hydrolysis 
of the ester backbone in body fluid. The 
degradation products (i.e. lactic and glycolic 
acids) are metabolic compounds and readily 
eliminated from the body through Krebs cycle [6]. 
Due to these characteristics, these polymers 
have the advantage of not requiring surgery for 
removal from the body after they have served 
their purposes. They protect the entrapped drug 
against degradation and control its site specific 
release. PLGA is synthesized through ring-
opening polymerization of two different 
monomers, the cyclic dimers (1, 4-dioxane-2, 5-
diones) of glycolic acid and lactic acid. During 
polymerization, successive monomeric units (of 
glycolic or lactic acid) are linked together in 
PLGA by ester linkages, thus yielding a linear, 
aliphatic polyester as a product [7]. The poly(D, 
L-lactide-co-glycolide) synthetic scheme is 
described in Figure 1.  
 
Effect of PLGA properties on drug release 
 
With varying the ratio of lactide to glycolide, 
amorphous and crystalline forms of PLGA can be 
obtained. It has been found that the time required 
for hydrolytic degradation of PLGA is related to 
the lactide to glycolide ratio, end group (ester or 
free carboxyl group) and molecular weight of 
polymer. As the most frequently used 
biodegradable polymer for drug loaded 
microsphere/nanospheres preparation, the effect 
of different PLGA properties such as molecular 
weight, lactide/glycolide ratio, and the end group 
capping on drug release have been extensively 
studied. Low molecular weight PLGA generally 
leads to a faster polymer degradation and a more 
rapid drug release [17,18]. As lactide is more 
hydrophobic than glycolide, an increase in lactide 
content in PLGA copolymers decreases the 
polymer degradation rate and results in a slower 
drug release [19]. The end group of PLGA is a 
factor that affects the hydrophilicity of the 
polymer. In general, PLGA copolymers carrying 
free carboxylic end groups caused a high initial 
burst and release rates compared to the end-
capped polymer [20]. Uncapped PLGA with free 
carboxyl termini is more hydrophilic and absorb 
more water, leading to a higher degradation rate 
than its end-capped species with esterified 
carboxyl termini [21]. Thus, the physical and 
chemical characteristics of PLGA such as 
molecular weight, copolymer ratio, ester or free 
carboxyl end groups and glass transition 
temperature are important factors for the 
biodegradability of the polymers. 
 
PLGA of varying molecular weight (ranging from 
10 to > 100 kDa) and different lactide to glycolide 
molar ratios (50:50, 65:35, 75:25, and 85:15) is 
available on the market. Normally, 50:50 
lactide/glycolide PLGA copolymers have the 
fastest half-life of degradation, around 50-60 
days, whereas 65:35, 75:25, and 85:15 
lactide/glycolide copolymers have progressively 
longer degradation half-lives in vivo. 
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Fig 1: Pol(D, L-lactide-co-glycolide) (PLGA) synthetic schemes 
 
Table 1 exhibits some physical properties of 
different PLGA. The half-life of these polymers 
can be decreased or increased by co-blending 
with more hydrophilic or hydrophobic compounds 
such as polyethylene glycol or polycaprolactone. 
Visscher et al studied the biodegradation of 
poly(D,L-lactide) and 50:50 poly(D,L-lactide-co-
glycolide) in rat gastrocnemius muscles [22,23]. 
Poly(D,L-lactide) nanoparticles was completely 
degraded within 480 days, whereas the PLGA 
nanoparticles was degraded in 63 days. This 
happened due to more hydrophilic and 
semicrystalline nature of the glycolide part. Thus, 
PLGA with 50:50 lactide to glycolide ratio is more 
advantageous than other polymers due to its 
fastest degradation rate and thus resulting in a 
faster drug release from the nanoparticles. 
 
Glass transition temperature (Tg) is the 
temperature at which the polymers change from 
glassy state to rubbery state. At this point, the 
mechanical behavior of the polymer changes 
from rigid and brittle to tough and leathery 
(plastic behavior). The Tg of PLGAs is commonly 
above the physiological temperature of 37 °C, 
which gives them enough mechanical strength to 
be fabricated into delivery devices. The Tg of the 
PLGA decreases with decrease of lactic acid 
content in copolymer and with decrease in their 
molecular weight [24]. 
 
Microspheres and nanospheres based on PLGA 
have been extensively investigated for sustained 
and targeted release of drugs such as anticancer 
drugs [25], antibiotics [26-28], peptide and 
protein drugs namely human growth hormone 
[29], leuprolide acetate [30], octreotide [31], 
lysozyme [32], bovine serum albumin (BSA) [33] 
and insulin [34]. 
 
 
















PLGA (50:50) 0.55-0.75 Amorphous 45-50 1,2,3,4,5,6 1-2 
PLGA (65:35) 0.55-0.75 Amorphous 45-50 1,2,3,4,5,6 3-4 
PLGA (75:25) 0.55-0.75 Amorphous 50-55 1,2,3,4,5,6 4-5 
PLGA (85:15) 0.55-0.75 Amorphous 50-55 1,2,3,4,5,6 5-6 
*1 = acetone, 2 = tetrahydrofuran, 3 = hexafluoroisopropanol, 4 = chloroform, 5 = ethylacetate, and 6 = 
dichloromethane
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POLYESTERS FOR NANOPARTICLE 
PREPARATION 
   
Most polyesters do not have significant number 
of functional groups that could enhance their 
potential applications. Recently, extensive work 
has been carried out towards functionalizing 
polyesters in order to enhance the drug delivery 
behavior of the synthesized nanoparticles. The 
introduction of functional pendant groups in side 
chains along the polymer backbone can be used 
to alter the key properties of these polyesters. 
Functional aliphatic polyesters can be 
synthesized by two different synthetic methods 
(1) the functionalization of pre-formed PLGA, and 
(2) the polymerization of functionalized 
monomers/dimers. Practically, the second 
protocol is preferred, due to the risk of side 
reactions (e.g. chain scission and racemization) 
associated with the first protocol. The 
polymerization of functionalized mono/dimers 
can generally be conducted via: (i) 
polycondensation, (ii) ring-opening 
polymerization (ROP), or (iii) enzymatic 
polymerization. Ring opening polymerization 
(ROP) is often preferred method. Since, high 
molecular weight polymers can be obtained 
easily in a controlled manner in contrast to the 
other two methods.  
 
A variety of functionalized polyesters containing 
different types of side chains and end groups 
have been synthesized in recent years [35-37]. 
An interesting type of functionalized polyester, 
poly(lactic-co-hydroxymethyl glycolic acid) 
(PLHMGA) has been synthesized by Hennink 
and co-workers [38,39]. This functionalized 
polymer (Figure 2) containing side chains with 
free OH groups are more hydrophilic than 
conventional PLGA. The introduction of OH 
groups provide polymers with tunable 
degradation behavior by suppression of 
crystallinity and enhanced hydrophilicity which 
improve cell adhesion. Thus, an increased 
hydrophilicity results in a greater water uptake 
capacity of the polymers, thereby increasing the 







Figure 2: Functionalized poly(lactic-co-hydroxymethyl 
glycolic acid) (PLHMGA) polymer 
PREPARATION OF DRUG LOADED 
POLY-MERIC NANOPARTICLES 
 
Several methods have been developed to 
prepare drug loaded micro and nanoparticles 
with desired release characteristics from 
biodegradable polymers. These include: 
emulsification solvent evaporation [40], 
nanoprecipitation [41], emulsification solvent 
diffusion method [42] and salting out [43]. The 
use of a particular method in the preparation of 
drug loaded nanoparticles depends on the nature 
of the polymer employed, nature of the drug to 
be encapsulated, intended use of the system, 
and intended duration of the therapy. In vitro and 
in vivo responses from the nanoparticles are 
influenced by their various properties, such as 
the particle size and size distribution, surface 
morphology, porosity, surface chemistry, surface 
adhesion, zeta-potential, drug stability, drug 
encapsulation efficiency, surface/bulk 
erosion/degradation, diffusion of the drug, 
kinetics of drug release, and the thermodynamic 
properties of the nanoparticles. 
 
Depending on the preparation methods drugs or 
antigens can either be entrapped in the polymer 
matrix, encapsulated in a liquid core, surrounded 
by a shell-like polymer membrane, or bound to 
the particle surface by adsorption [44]. For drug 
loading into nanoparticles, three major strategies 
can be employed: (1) covalent attachment of the 
drug to the particle surface or to the polymer 
prior to preparation, (2) adsorption of the drug to 
a preformed carrier system, and (3) incorporation 
of the drug into the particle matrix during particle 
preparation [45]. The release rates of 
nanoparticles depend upon: (i) desorption of the 
surface-bound/adsorbed drug, (ii) diffusion 
through the nanoparticle matrix, (iii) diffusion (in 
case of nanocapsules) through the polymer wall, 
(iv) nanoparticle matrix erosion, and (v) a 
combined erosion/diffusion process. During 
these preparation and release processes, the 
bioactivity of therapeutic agents must be 
remained in native form. 
 
Emulsification-solvent evaporation method 
 
There are single (O/W) and double (W/O/W) 
emulsion systems in this fabrication method. 
Single emulsion method is conducted for the 
formulation of hydrophobic drugs (oil soluble); 
while double emulsion is adopted for the 
encapsulation of hydrophilic drugs (peptide and 
protein drugs). 
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Water/oil/water (W/O/W) double emulsion 
solvent evaporation method 
 
The W/O/W double emulsion solvent evaporation 
method has been widely used due to its relatively 
simple process, convenience in controlling 
process parameters, and ability to produce with 
inexpensive instrument [46]. In this method, the 
polymer is first dissolved in a water-immiscible, 
volatile, organic solvent. Usually, 
dichloromethane (DCM) is selected as organic 
solvent, but other solvents like chloroform, ethyl 
acetate or methylethyl ketone have also been 
investigated. An aqueous solution of hydrophilic 
drug is added to this polymer solution and the 
mixture is emulsified by a high speed 
homogenizer or a sonicator to form the first W/O 
emulsion. Then, the primary W/O emulsion is 
further added gently with stirring into a large 
volume of outer water phase containing 
surfactant, such as poly(vinyl alcohol) (PVA), 
resulting in a W/O/W double emulsion. 
 
The selection of surfactants in the outer water 
phase is an important factor for successful nano 
or microparticles fabrication. The aggregation of 
PLGA particles during the process of particle 
formation is a major problem regardless of the 
fabrication method. In order to prevent the 
aggregation of PLGA particles, polymer 
stabilizers are often used. Furthermore, the size 
and shape of the particles can also be influenced 
by the stabilizer used.  
 
Surfactants or stabilizers are amphiphilic 
molecules that posses both hydrophilic and 
hydrophobic parts. The hydrophilic moiety is 
called the head and the hydrophobic part the tail. 
The head can be charged or uncharged polar 
group. Depending on the nature of head groups, 
different kinds of surfactants such as non-ionic 
surfactant poly(vinyl) alcohol (PVA) [47], anionic 
surfactant sodium dodecyl sulphate (SDS) [48], 
cationic surfactant didodecyl dimethyl ammonium 
bromide (DMAB) [49], and amphiphilic surfactant 
d-α-tocopheryl polyethylene glycol 100 succinate 
vitamin E (TPGS) [50] are commonly applied 
based on emulsion systems. 
 
To harden the nanoemulsion droplets into solid 
nanoparticles, the organic solvent is removed by 
either solvent extraction or solvent evaporation 
and the nanoparticles are collected by filtration or 
centrifugation. For the removal of solvent, the 
stirring process may be continued for several 
hours at high-temperature/low-pressure 
conditions. The properties of nanoparticles such 
as drug loading capacity (LC), encapsulation 
efficiency (EE), release profiles and morphology 
(shape and size) depend on various parameters 
such as drug (type and concentration), polymer 
(composition, molecular weight, and 
concentration), volume ratio between drug and 
polymer solution, emulsification method 
(homogenization time and speed), surfactant 
(types and concentration) additives in the internal 
water phase and external water phase (e.g., 
NaCl, NaHCO3, sucrose ) [51-53]. 
 
Bilati et al [15] investigated the effect of polymer 
type on drug encapsulation efficiency (EE) and 
mean size of protein loaded PLGA nanoparticles 
prepared by a W/O/W double emulsion method. 
From the Table 2 it was found that when the 
molecular weight of PLGA was higher the EE 
was enhanced and the particles were larger. The 
effect of high molecular weight PLGA on particle 
size seems to be independent of protein loadings 
but might be due to longer polymeric chains and 
their higher inherent viscosities. The use of 
PLGA with uncapped carboxylic end groups 
having a molecular weight of 34 kDa, The EE 
was 97 %, while the size was 271 nm. This 
increase in EE is due to an ionic interaction 
between the positively charged amino groups of 
proteins and the negative charges of the 
copolymer carboxylic acids [54]. A large particle 
size 1090 nm (i.e. so-called microparticles) was 
observed when the polymer concentration was 
doubled. This effect of polymer concentration on 
particle size might be due to the increased 
viscosity of the organic phase. 
 
In W/O/W technique, proteins encapsulated into 
PLGA nano or microparticles are susceptible to 
denaturation or aggregation, oxidation, 
deamidation and cleavage, while creating the 
W/O primary emusion [55]. A large interface 
between the aqueous and organic phase is 
formed in this process, at which the protein may 
adsorb and denature. Protein stability may be 
enhanced if the protein is encapsulated as a 
solid rather than in solution. So, the modification 
of this method has been developed to solve 
those problems. 
 
Solid/oil/water (S/O/W) double emulsion 
solvent evaporation method 
 
Protein adsorption and denaturation at the 
aqueous/organic solvent interface is one of the 
major limitations for decreased protein bioactivity 
occurring during the encapsulation process. To 
protect protein from denaturation during 
formation of W/O emulsion, S/O/W method has 
been developed. This is because, proteins in the 
Ansary et al 
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solid state are believed to maintain their 
bioactivity by drastically reducing conformational 
change in comparison to the large structural 
change found in the dissolved state [56]. In the 
S/O/W method, dehydrated protein powders are 
dispersed in the polymer solution to form the 
primary emulsion. Then the solid dispersion is 
introduced into a large volume of aqueous 
solution containing surfacting agent, such as 
PVA. It can be noted that making dispersion of 
protein particles in organic solvent is not so easy. 
Protein particle micronization is one of the major 
challenges in the S/O/W method which include 
lyophilization, spray drying, and spray freeze-
drying [57]. Spray freeze-drying collects 
atomized protein microdroplets in a frozen form 
and followed with the ice sublimation under 
reduced pressure. Thus, the temperature 
dependent protein denaturation and deactivation 
experienced in spray drying is circumvented. 
Nevertheless, one of the problems hampering 
the use of S/O/W technique is the low 
encapsulation efficiency of proteins. It is notable 
that encapsulation yield is an important 
parameter for cost-efficient production of 





Nanoprecipitation or solvent displacement 
method was introduced by Fessi and co-workers 
and has become a popular technique to prepare 
nanoparticles due to narrow size distribution, 
absence of shear stress, and absence of 
surfactants for amphiphilic polymers [41]. In this 
method, particles are formed spontaneously by 
precipitation and subsequent solidification of the 
polymer upon rapid solvent diffusion. The 
polymer and drug are dissolved in a water 
miscible organic solvent for example acetone or 
methanol. The solution is then poured under 
magnetic stirring into an aqueous solution which 
contains surfactant. Through rapid solvent 
diffusion, the nanoparticles are formed 
immediately. After that, the solvents are removed 
under reduced pressure. The mechanism of 
formation of NPs by this technique has been 
explained by the interfacial turbulence generated 
at the interface of the solvent and non-solvent. 
Thus, the process is often called solvent 
displacement or interfacial deposition. 
 
Emulsification solvent diffusion method 
 
In this technique, the organic solvent containing 
the dissolved polymer and the drug is emulsified 
in an aqueous surfactant solution (usually with 
PVA as a stabilizing agent) by using a high-
speed homogenizer. Water is subsequently 
added under constant stirring to the O/W 
emulsion system, thus causing phase 
transformation and outward diffusion of the 
solvent from the internal phase, leading to the 
nanoprecipitation of the polymer and the 
formation of colloidal nanoparticles. Finally, the 
solvent can be eliminated by vacuum steam 
distillation or evaporation. The most important 
fabrication step is solvent diffusion, in which the 
organic phase diffuses from the oil phase to 
outer water phase and the formed particles 
become hardened. The selection of the 
surfactants in the outer water phase is also 




Salting out is another fabrication method for the 
preparation of PLGA nanoparticles. In this 
method, firstly PLGA is dissolved in a water 
miscible organic solvent such as tetrahydrofuran 
(THF) or acetone. Then, the oil phase is 
emulsified in an aqueous phase consisting of 
surfactant and salt of high concentration under 
strong shearing force by an overhead 
mechanical stirrer. Typically, the most commonly 
used salts are magnesium chloride hexahydrate 
or magnesium acetate tetrahydrate with a ratio of 
 
Table 2: Effect of polymer type on encapsulation efficiency (EE) and mean size of protein-loaded PLGA 
nanoparticlesa [15] 
 




Volume of inner 
phase(w) (µL) 
EE (%) Size (nm) 
PLGA 34 200 100 81 288 
PLGA 12 200 100 89 207 
PLGA 80 200 100 98 408 
PLGA-H 34 200 100 97 271 
PLGA 34 200 200 94 378 
PLGA 34 400 200 84 1090 
a All batches were produced with ethyl acetate as organic solvent and at 1% of nominal DL; b PLGA = Resomer® 
RG 502, RG 503 or RG 505;  PLGA-H = Resomer® RG 503 with uncapped carboxylic end groups 
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Table 3: Some marketed formulations of proteins based PLGA micro/nanooparticles [59] 
 
Product name Active ingredient Company Application 
Lupron Depot®  Leuprolide acetate TAP Prostate cancer 
Nutropin Depot®  Growth hormone Genetech Pediatric growth hormone deficiency 
Suprecur® MP Buserelin acetate Aventis Prostate cancer 
Decapeptyl®  Triptorelin pamoate Ferring Prostate cancer 
Sandostatin LAR® Depot  Octreotide acetate Novartis Acromegaly 
Somatuline® LA Lanreotide Ipsen Acromegaly 
Trelstar™ Depot Triptorelin pamoate Pfizer Prostate cancer 
Arestin® Minocycline Orapharma Periodontal disease 
Risperidal® Consta™ Risperidone Johnson & Johnson Antipsychotic 
 
1:3 (polymer to salt) [58]. The main difference 
between the emulsion diffusion and salting out 
method is that for the second one there is no 
solvent diffusion due to presence of salts. This is 
because, addition of pure water into the formed 
O/W emulsion under magnetic stirring reduced 
the ionic strength of salt. At the same time, the 
hydrophilic organic solvents migrate from the oil 
phase to the aqueous phase resulting in the 
formation of nanoparticles. Finally, the salting out 
agent is removed by centrifugation. 
 
BIODEGRADABLE PLGA MICRO/ 
NANOPARTICLES AS PROTEIN 
DELIVERY SYSTEM 
 
Various therapeutic peptides and proteins 
encapsulated PLGA micro and nanoparticles 
have recently received much attention for their 
application of sustained release over an 
extended period. Since this technology provides 
unique advantages over traditional delivery 
approaches (e.g., improved drug efficacy and 
patient compliance), several formulations of 
proteins based on biodegradable 
micro/nanoparticles have already been 
marketed, as shown in Table 3 [59]. Since 
proteins are hydrophilic, high molecular weight 
macromolecules, and unstable to various 
detrimental environments, low encapsulation 
efficiency, incomplete and erratic release profiles 
are the most common features of controlled 
release protein delivery system using PLGA [32]. 
Denatured or aggregated protein species will not 
only be therapeutically inactive, but also may 
cause unpredictable side effects, such as 
immunogenicity or toxicity [60]. In the past two 
decades, many strategies have been 
investigated for the sustained, complete and 
native form of protein release from PLGA based 
micro and nanoparticles. 
 
Approaches to retain protein integrity in 
PLGA-based micro/nanoparticles 
 
The presence of water/solvent interface is one of 
the major factors for decreased protein bioactivity 
occurring during the emulsion method. In this 
emulsion preparing step, protein is exposed to 
large extent of water/organic interface, resulting 
in protein aggregation. The extent of protein 
aggregation depends on the nature of solvents. 
Dichlorometane (DCM) induces more protein 
aggregation than ethyl acetate [61]. The extent of 
protein aggregation during emulsification also 
depends on the methods of emulsification. It has 
been found from the study on the effect of 
different emulsification methods that sonication 
and vortex mixing generated slightly increased 
aggregation than homogenization [62].  
 
Role of viscous microenvironment in 
reducing protein denaturation 
 
A variety of stabilizing interface-active excipients 
such as sugars (e.g., trehalose, sorbitol) [61,63], 
polyethylene glycol (PEG) [64] are added into the 
internal protein solution to protect protein from 
aggregation as well as denaturation during 
emulsification. These excipients either reduce 
the protein adsorption at the water/organic 
solvent interface by competitive adsorption from 
additives (PEG, carrier proteins), or to 
accumulate at the water/organic solvent 
interface, thereby shielding proteins from 
degrading environment [9].  
 
Jintian et al [65] prepared recombinant human 
erythropoietin (rhEPO) loaded PLGA 
microspheres using human serum albumin (HSA) 
as a stabilizer by a modified S/O/W technique. 
They claimed that the integrity of rhEPO was 
protected during the encapsulation process and 
33 days release period from the polymeric 
Ansary et al 
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matrices. Insulin encapsulated PLGA 
microspheres were prepared by a modified O/O 
solvent evaporation method [66]. In this single 
phase O/O method insulin instability problems 
were minimized as no aqueous organic interface
was involved, and high sheering mixers 
(homogenizer or sonicator/or freeze-drying 
techniques) were not applied. 
 
Role of basic salts in reducing pH-induced 
protein denaturation 
 
The degradation of biodegradable PLGA delivery 
matrices leads to generation of acidic oligomers 
(lactic/glycolic acids) which results in increase in 
acidity of microenvironment. This drop of pH in 
the microenvironment induces protein 
degradation. To overcome acidic microclimate 
within the device, basic salts such as NaHCO3, 
ZnCO3, MgCO3, or Mg(OH)2 has been found to 
be used as buffering agents into matrix to 
counteract acidic microenvironment. Zhu et al 
[67] reported that polymer microclimate has an 
acidic pH (less than 3) and it triggers unfolding of 
proteins like bovine serum albumin (BSA). To 
neutralize the acids liberated by the 
biodegradable lactic/glycolic acid polymers, they 
incorporated antacid Mg(OH)2 which increased 
the microclimate pH and prevented bovine serum 
albumin (BSA) structural losses and aggregation 
for over 1 month.  
 
Rafi et al [68] reported that incorporation of HSA 
and NaHCO3 during particle formulation 
stabilized the recombinant human growth 
hormone (r-hGH) inside the PLGA microparticles. 
Three different zinc salts (i.e., zinc oxide, zinc 
carbonate, and zinc acetate) were incorporated 
in the preparation of insulin loaded PLGA 
microspheres [34]. Insulin secondary structure 
was unaltered due to the addition of zinc salts as 
compared to the formulation prepared without a 
zinc salt. They reported that formation of 
hexamers in presence of zinc salt was the major 
reason of improved insulin stability. In most 
cases, the buffering approach increased the 
stability of the released protein in vitro. 
Nevertheless, protein release profiles from PLGA 
microspheres were not fully controlled. So, the 
addition of other excipients or incorporation a salt 
in a different way is very important for 
maintaining protein stability and release kinetics.  
 
Role of functionalized hydrophilic polymers 
in reducing protein denaturation 
 
Due to the hydrophobic nature of PLGA, a slower 
release rate of recombinant human insulin-like 
growth factor-I (rhIGF) and of a somatostatin 
analogue have been observed [69,70]. So, the 
use of promising new polymers that are more 
hydrophilic than PLGA have emerged. These 
polymers are more compatible with proteins; 
especially since they reduce protein absorption 
and favour homogeneous distribution within the 
matrix. Moreover, they increase water uptake 
within the microspheres. To enable a better 
water uptake and an easier diffusion of the 
protein and of the polymer degradation products 
out of the polymer, porous microspheres were 
prepared by a range of groups.  
 
Biodegradable PLA or PLGA have been co-
dissolved with various biocompatible hydrophilic 
or amphiphilic compounds in the encapsulation 
procedure to prevent acidic microclimate-induced 
instability reactions of proteins in degrading 
polymers. For instance, PLGA was blended with 
pore-forming PEG in order to enhance the 
release of EPO and insulin [71,72]. But, a burst 
and a steady rate of protein release in vitro were 
observed over 1 month. Complete release was 
not reached due to the presence of protein 
aggregates. Ghassemi et al [73] recently 
formulated microspheres from a novel 
functionalized hydrophilic aliphatic polyester, 
PLHMGA for reducing the pH induced 
aggregation of therapeutic proteins. From the in 
vitro release studies, they reported that the 
release of lysozyme was incomplete, likely due to 
aggregation of part of the encapsulated protein. 
 
ORAL DELIVERY FORMULATIONS OF 
PROTEIN/ PEPTIDE-LOADED PLGA 
NANOPARTICLES 
 
For the treatment of Type 1 diabetic patients, 
three subcutaneous injections are required daily 
to maintain the blood glucose level. The daily 
injection routine is inconvenient for patients due 
to pain, tenderness, local tissue necrosis, 
microbial infection and fear of hypoglycemia. 
Oral delivery of insulin is expected to overcome 
these problems. For many years various 
unsuccessful approaches have been developed 
for oral delivery of insulin [74,75]. The reasons 
for failure of oral delivery of bioactive 
macromolecules include the acidic environment 
of the stomach, rapid enzymatic degradation and 
the poor intestinal absorption [76]. Recently, Zhi 
et al [77] developed a two-stage delivery system 
for oral delivery of insulin. The system composed 
of pH-sensitive hydroxypropyl methyl cellulose 
phthalate (HP 55) coated capsule containing 
insulin loaded PLGA and Eurdragit® RS (RS) 
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cationic nanoparticles. In this study, insulin was 
protected from rapid enzymatic degradation in 
gastrointestinal (GI) tract due to the coating of 
hard gelatin capsules by pH sensitive HP 55. 
Whereas, PLGA/RS cationic nanoparticles were 
adhered to the intestinal mucosa resulting in a 
improved absorption of insulin across the 
intestinal epithelial cells. In another study, 
Sharma et al [78] developed antacid-insulin co-
encapsulated PLGA nanoparticles for oral 
delivery of insulin. They investigated both in 
vitro/in vivo studies of the prepared 
nanoparticles. From the in vitro test, they claimed 
that encapsulated insulin was well protected 
under simulated gastric and intestinal fluids. 
From the in vivo test, they showed that in 
diabetic rats, a 120 IU/Kg oral dose of insulin 
nanoparticles achieved an equivalent blood 
glucose lowering effect to a 20 IU/Kg 
subcutaneous dose of insulin solution. From this 
studies, they concluded that although oral 
delivery of insulin was achieved, further 
improvements is required to increase the Cmax 
(maximum concentration attained in plasma) and 
to reduce the Tmax (time to attain maximum 
plasma concentration) for successful oral 




This review outlines the present research and 
development activities on PLGA and PLGA-
based micro/nanoparticles as protein and peptide 
drug delivery devices. A deep understanding of 
the effects of fabrication methods, PLGA, 
surfactants and excipients nature is necessary 
for the formulation of protein loaded 
micro/nanoparticles with desired protein release 
profiles and structural integrity (i.e., bioactivity). 
Another important factor has to be considered in 
drug loading is protein encapsulation efficiency 
(EE). Since protein drugs are usually extremely 
expensive, achieving the high EE is very 
essential to reduce the loss of expensive drug. 
The method of making protein drugs stable for 
extended period of time in the body condition has 
to be incorporated into the micro/nanoparticle 
preparation method. All the above mentioned 
factors need to be understood for successful 
development of long-term protein delivery 
systems using biodegradable PLGA micro or 
nanoparticles. Although many advances have 
been made for formulation of successful protein 
delivery devices, much work still remains before 
proteins can be used as a therapeutic molecule 
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